貴研鉑業(600459.SH)擬6億元設立貴研化學公司 開展貴金屬化學材料開發業務
格隆匯3月4日丨貴研鉑業(600459.SH)公佈,公司擬投資人民幣6億元設立全資子公司貴研化學材料(雲南)有限公司(以工商註冊登記為準,以下簡稱“貴研化學公司”),開展貴金屬化學材料開發、生產以及銷售等業務。
投資設立貴研化學公司符合公司貴金屬化學材料工藝技術升級、綜合供應保障能力升級的實際需要。有利於促進公司集中優勢資源,拓展在貴金屬化學材料領域的核心業務,謀求更大的發展空間;有利於鞏固並不斷提升公司在貴金屬化學材料領域的市場份額,提升公司在該領域的影響力;有利於進一步提升公司在貴金屬新材料製造領域的綜合競爭實力和盈利能力,符合公司貴金屬產業優化佈局和可持續發展的戰略需要。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.